Nektar Therapeutics stock trails UBS target by 32.49 percent on October 16

Published on 10/17/2026 at 20:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter 2026 revenue was USD 10.13 million. Nektar Therapeutics stock last stood at USD 35.78 on October 16, 2026, down 5.14 percent on Nasdaq.

Analyst target and price placement

UBS assigned a USD 53.00 target and Hold rating to Nektar Therapeutics on October 12, 2026.
Second-quarter 2026 revenue was USD 10.13 million versus USD 10.43 million expected.
Nektar Therapeutics stock was last at USD 35.78 on October 16, 2026 at 4:00 p.m. ET, down 5.14 percent on Nasdaq.
Nektar had a USD 1.0 billion market capitalization and a negative P/E ratio of 5.34 on October 16, 2026.

NKTR, US6402683063, Illustration mit AI erstellt.

Nektar Therapeutics stock sat 32.49 percent below the USD 53.00 UBS target on October 16, 2026, based on the latest Nasdaq price of USD 35.78. According to The Globe and Mail, UBS analyst Alice Nettleton assigned the Hold rating and target on October 12, 2026. Nektar's stock was last at USD 35.78 on October 16, 2026 at 4:00 p.m. ET, down 5.14 percent from the Nasdaq prior close.

Second-quarter revenue missed estimates

Nektar reported USD 10.13 million in revenue for the second quarter of 2026, below the USD 10.43 million consensus estimate. The company also reported a loss of USD 1.23 per share, while the consensus loss was USD 1.97 per share, a difference of USD 0.74 per share.

MarketBeat reported the quarterly figures and identified Nektar as a Nasdaq-listed biotechnology company. The company remains focused on therapies for cancer and autoimmune diseases, giving the earnings comparison a clinical-development context.

Price position on October 16

The USD 35.78 last price stood above the 52-week low of USD 33.40 and below the 52-week high of USD 109.00. Trading volume was 784,232 shares against an average of 1,114,998 shares, or 29.66 percent below the average.

Valuation and upcoming dates

Nektar's market capitalization was USD 1.0 billion on October 16, 2026. Its negative P/E ratio was 5.34, while the company held USD 39.27 million in cash at June 30, 2026.

The investor-relations page lists an October 1, 2026 analyst and investor event at the European Academy of Dermatology and Venereology Congress. It also lists new rezpegaldesleukin data dated October 1, 2026, extending the clinical-development calendar around the company.

Comparison with peers

Nektar Therapeutics (Nasdaq, USD): minus 5.14 percent, P/E -5.34, market capitalization USD 1.0 billion
Arrowhead Pharmaceuticals (Nasdaq, USD): minus 4.44 percent, P/E -24.96, market capitalization USD 7.9 billion
Immunocore Holdings (Nasdaq, USD): minus 0.27 percent, P/E -154.49, market capitalization USD 1.5 billion

Stock position after October 16

The latest Nasdaq price leaves Nektar well below its 52-week high while remaining only 7.13 percent above its 52-week low. The UBS target places a second valuation marker above the current quotation, but the second-quarter revenue comparison shows that clinical progress remains central to the investment case.